Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 1—January 2025
CME ACTIVITY - Synopsis
Pneumococcal Septic Arthritis among Adults, France, 2010–2018
Table 1
Characteristic |
2017 guidelines |
2023 guidelines |
Age ≥65 y | No recommendation |
No recommendation |
Alcohol use | ||
Active smoking |
||
Immunocompromised patients: asplenia or hyposplenia, hereditary immune deficiency, HIV infection, solid organ transplant, hematopoietic stem cell, chronic autoimmune or inflammatory disease treated by immunosuppressive or biological drugs, nephrotic syndrome, or patients treated by chemotherapy for a solid tumor or hematologic malignancy | 1 dose of PCV13 + 8 weeks later: 1 dose of PPV23 + 5 years later: 1 dose of PPV23 |
1 dose of PCV20 |
Patients with chronic diseases: chronic respiratory disease, severe asthma, heart failure or cyanotic heart disease, renal failure, chronic liver disease, diabetes mellitus, osteomeningeal breach, or cochlear implant |
*PCV13,13-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; PPV23, 23-valent pneumococcal polysaccharide vaccine.
Page created: December 02, 2024
Page updated: December 19, 2024
Page reviewed: December 19, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.